SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
833Almost 2 years at the same job these days is long term :)rkrw-9/1/2007
832I have no idea but a GC who is merely a VP and not part of the executive team, nkeokalani'nui-9/1/2007
831Item 5.02. Departure of Directors or Certain Officers; Election of Directors; ApIcebrg-9/1/2007
830[Intratumor Injection of the Hsp90 Inhibitor 17AAG Decreases Tumor Growth and Intuck-8/22/2007
829[Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplastuck-8/22/2007
828Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinicamopgcw-8/10/2007
827[17-AAG inhibits the growth of GL261 glioma cells in vitro and in vivo] >>tuck-8/2/2007
826[Extracellular Hsp90: A role for a molecular chaperone in cell motility and canctuck-7/25/2007
825[Inhibition of the MAPK pathway results in the down-regulation of P-glycoproteintuck-7/11/2007
824[17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells] &tuck-7/11/2007
823Phase II study of KOS-862 in patients with metastatic androgen independent prostIcebrg-7/11/2007
822Hsp90 Inhibitors Prolong Survival, Attenuate Inflammation and Reduce Lung InjuryIcebrg-7/10/2007
821Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Icebrg-7/6/2007
820[Small Molecule Inducers of Heat-Shock Response Reduce polyQ-Mediated Huntingtintuck-6/29/2007
819Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilIcebrg-6/28/2007
818Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinIcebrg-6/28/2007
817FDA Grants Priority Review for Bristol-Myers Squibb's Investigational OncoloIcebrg-6/19/2007
816The Next Wave of Cancer Drugs There's a buzz among doctors and researchers aIcebrg-6/6/2007
815Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, AlveIcebrg-6/4/2007
814Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety ProfIcebrg-6/4/2007
813Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 InhiIcebrg-6/4/2007
812Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising AntIcebrg-6/4/2007
811Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Icebrg-6/4/2007
810>>Kosan Announces Data Presentations at ASCO 2007 Annual Meeting Wednesdaytuck-5/23/2007
809Targeting HSP90 enhances PDT therapy. Will deals be forthcoming with Phamacyclituck-5/23/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News